DVAX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -140.98% compared to Dynavax Technologies's net margin of 19.72%. Dynavax Technologies's return on equity of -9.78% beat Gilead Sciences's return on equity of 32.29%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 136.29%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 10.81%. Given that Dynavax Technologies has higher upside potential than Gilead Sciences, analysts believe Dynavax Technologies is more attractive than Gilead Sciences.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.99% to investors and pays a quarterly dividend of $0.79 per share. Dynavax Technologies pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Dynavax Technologies's net income of -$96.1M is lower than Gilead Sciences's net income of $1.3B. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Gilead Sciences's PE ratio is 21.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.74x versus 4.56x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -140.98% compared to Dynavax Technologies's net margin of -111.65%. Dynavax Technologies's return on equity of -9.78% beat Ionis Pharmaceuticals's return on equity of -100.15%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 136.29%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.54 which suggests that it could grow by 71.61%. Given that Dynavax Technologies has higher upside potential than Ionis Pharmaceuticals, analysts believe Dynavax Technologies is more attractive than Ionis Pharmaceuticals.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.865%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $131.6M. Dynavax Technologies's net income of -$96.1M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.74x versus 7.14x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -140.98% compared to Dynavax Technologies's net margin of 21.68%. Dynavax Technologies's return on equity of -9.78% beat Eli Lilly and's return on equity of 78.25%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 136.29%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 29.55%. Given that Dynavax Technologies has higher upside potential than Eli Lilly and, analysts believe Dynavax Technologies is more attractive than Eli Lilly and.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Dynavax Technologies pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Dynavax Technologies's net income of -$96.1M is lower than Eli Lilly and's net income of $2.8B. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Eli Lilly and's PE ratio is 61.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.74x versus 13.93x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -140.98% compared to Dynavax Technologies's net margin of -907.48%. Dynavax Technologies's return on equity of -9.78% beat Moderna's return on equity of -29.23%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 136.29%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 82.73%. Given that Dynavax Technologies has higher upside potential than Moderna, analysts believe Dynavax Technologies is more attractive than Moderna.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Moderna quarterly revenues of $107M. Dynavax Technologies's net income of -$96.1M is higher than Moderna's net income of -$971M. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.74x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.